■ Implandata Ophthalmic Products has announced the European launch of its web-based Eyemate IOP-Tracking Service for remote monitoring and management of glaucoma. The Eyemate provides eye doctors with IOP measurements collected anytime under patients’ normal life conditions.

The Eyemate system consists of a permanent implantable and biocompatible microsensor, which takes IOP measurements. The microsensor is powered by an external handheld device, which transfers energy to the microsensor telemetrically and is responsible for data readout and storage.

“Remote IOP monitoring provides an immediate alert in case the therapy needs to be adjusted, without requiring an office visit,” said Kaweh Mansouri, MD, chief medical officer of Implandata, in a news release. “This is vital for controlling glaucoma, because IOP fluctuates continually without patients noticing it. The need for remote monitoring is even greater during stay-at-home orders, as we’re experiencing due to COVID-19; we can ensure that glaucoma care is well managed, without putting patients at risk.”

“Remote monitoring of IOP will transform glaucoma care,” said Robert N. Weinreb, MD, chair and distinguished professor of ophthalmology at the University of California, San Diego, in the news release. “The availability of large amounts of real-life IOP data will enable personalized glaucoma management to prevent vision loss.”

The Eyemate system is available in Germany, Switzerland, and the United Kingdom. The FDA Breakthrough Device approval process has been initiated in preparation for launching the Eyemate system in the United States.